Dietary Interventions in Asthma Treatment: Sprouts Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sulforaphane (SFN) is a naturally occurring isothiocyanate that is a potent inducer of Phase II enzymes which play a critical role in preventing oxidative stress (via activation of Nrf2). Broccoli sprouts (BS) contain the richest source of SFN.
The main objectives of this study are to test the effect of broccoli sprouts (BS) on biomarkers of oxidative stress (OS), inflammation, basophil activation, and clinical outcomes in mouse allergen-induced asthma by (1) determining if BS improves lung function and airways symptom responses in mouse-sensitized adults with asthma undergoing environmental mouse allergen challenge (EMAC), (2) examining the effect of BS on OS, inflammation, and basophil activation, and (3) examining the effect of BS on changes in OS, inflammation, and basophil activation after EMAC.
| Condition | Intervention | Phase |
|---|---|---|
|
Asthma Allergy |
Other: Broccoli Sprouts |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Dietary Interventions in Asthma Treatment: Sprouts Study |
- Forced expiratory volume in one second (FEV1) [ Time Frame: after 7 days of treatment ] [ Designated as safety issue: No ]
| Enrollment: | 38 |
| Study Start Date: | November 2010 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Broccoli Sprouts, then Alfalfa Sprouts |
Other: Broccoli Sprouts
Broccoli Sprouts will be eaten daily in a sandwich form.
|
| Alfalfa Sprouts, then Broccoli Sprouts |
Other: Broccoli Sprouts
Broccoli Sprouts will be eaten daily in a sandwich form.
|
Eligibility| Ages Eligible for Study: | 18 Years to 49 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18-49 years
- Physician-diagnosed asthma
- No other major pulmonary disease such as cystic fibrosis or COPD
- Mouse sensitization, defined by a positive skin prick test to mouse epithelial extract or positive mouse-specific IgE
- Non-smoker
Exclusion Criteria:
- Severe or unstable asthma defined as requiring hospitalization in the previous year or intubation in the previous 2 years, or on high-dose inhaled corticosteroids or chronic oral corticosteroids
- Baseline FEV1 and FEV1/FVC < 70% predicted
- Positive SPT to a pet currently living in the participant's home
- Other significant medical issues such as heart disease or poorly controlled hypertension, or hypothyroidism
- Pregnancy or nursing/breastfeeding mothers
- On beta-blocker therapy
- Taking anti-oxidant supplements
- Unable to stop antihistamines prior to skin testing
- Unable to stop medications that may interfere with allergen challenge responses prior to challenges.
- The participant has food allergy to BS or AS.
- Omalizumab use within the last 12 months.
- Oral corticosteroid use within the last 2 weeks.
Contacts and Locations| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21205 | |
| Principal Investigator: | Elizabeth C Matsui, MD MHS | Johns Hopkins University |
More Information
No publications provided
| Responsible Party: | Elizabeth Matsui, Associate Professor, Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT01183923 History of Changes |
| Other Study ID Numbers: | NA_00035087 |
| Study First Received: | August 17, 2010 |
| Last Updated: | March 28, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Johns Hopkins University:
|
asthma dietary interventions mouse allergy |
Additional relevant MeSH terms:
|
Hypersensitivity Asthma Immune System Diseases Bronchial Diseases Respiratory Tract Diseases |
Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate |
ClinicalTrials.gov processed this record on May 16, 2013